The back-and-forth between industry groups might obscure a positive trend: data showing U.S. drug price inflation has moderated in recent years. (Image: Shutterstock)
A pharmaceutical industry group is pushing back against a recent report that said some drug price increases were not supported by clinical improvement.
The Nov. 16 report by the Institute for Clinical and Economic Review (ICER) said that among the top 10 drugs with price increases in 2020 that had substantial effects on US spending, seven of 10 drugs did not have new evidence of a new clinical benefit. The report focused on Humira, a rheumatoid arthritis drug—which, by itself, accounted for $1.4 billion of the $1.67 billion in additional drug spending.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
